SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 11, 2015
INVUITY, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-37417 |
|
04-3803169 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File No.) |
|
(IRS Employer
Identification Number) |
444 De Haro Street
San Francisco, CA 94107
(Address of principal executive offices)
(650) 655-2100
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition.
On August 11, 2015, Invuity, Inc. (the Company) issued a press release announcing its financial results for the quarter ended
June 30, 2015. In the press release, the Company also announced that it would be holding a conference call on August 11, 2015 to discuss its financial results for the quarter ended June 30, 2015. The full text of the press release is
attached hereto as Exhibit 99.1 and is incorporated herein by reference.
This information is intended to be furnished under
Item 2.02 of Form 8-K, Results of Operations and Financial Condition and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or
incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibits.
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press release issued by Invuity, Inc. dated August 11, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
INVUITY, INC. |
Date: August 11, 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
By: /s/ Philip Sawyer |
|
|
|
|
|
|
Philip Sawyer |
|
|
|
|
|
|
President and Chief Executive Officer |
EXHIBIT INDEX
|
|
|
Exhibit No. |
|
Description |
|
|
99.1 |
|
Press release issued by Invuity, Inc. dated August 11, 2015. |
Exhibit 99.1
INVUITY REPORTS 2015 SECOND QUARTER,
SIX-MONTH FINANCIAL RESULTS
Second Quarter Revenue Increased 69 Percent Over Prior Year Period
SAN FRANCISCO, August 11, 2015 - Invuity, Inc. (NASDAQ:IVTY), a medical technology company, today reported financial results for the second
quarter and six-months ended June 30, 2015.
Q2 2015 Highlights
|
|
|
Revenue grew 69 percent to $4.7 million compared to revenue of $2.8 million in the 2014 second quarter. |
|
|
|
Revenue would have been $5.0 million, without the impact of a $300,000 adjustment. |
|
|
|
Invuity sold its devices to approximately 450 hospitals in the second quarter of 2015. |
|
|
|
In June 2015, Invuity closed its initial public offering (IPO) of 4,600,000 shares of common stock (including 600,000 shares purchased by the underwriters pursuant to an option to purchase additional shares) at the
public offering price of $12.00 per share, netting $47.2 million after all banker fees and issuance costs. |
Financial Results
Revenue was $4.7 million in the second quarter of 2015, compared to $2.8 million in the second quarter of 2014 and $4.4 million in the first quarter of 2015.
Revenue in the second quarter of 2015 would have totaled $5.0 million without the impact of an approximately $300,000 reversal of revenue that was originally recorded in the fourth quarter of 2014.
For the first six months of 2015, revenue was $9.2 million, up 85 percent from revenue of $5.0 million in the first six months of 2014.
Invuity has the unique opportunity to further expand its platform technology to enable new and emerging surgical procedures, said President and
CEO Philip Sawyer. We have built strong commercial momentum in our initial clinical areas and will continue to deliver devices and technologies that address additional specialties and new high volume procedures.
Gross margin for the second quarter and first six months of 2015 was 59 percent and 60 percent, respectively, compared to 55 percent and 59 percent for the
same periods in 2014.
Total operating expenses for the 2015 second quarter and first six months were $11.7 million and $22.5 million, respectively,
compared to $6.6 million and $12.4 million in the prior year periods.
The net loss for the second quarter of 2015 was $9.3 million, or $3.20 loss per share, compared to a net loss of
$5.5 million, or $8.40 loss per share, for the second quarter of 2014. The net loss for the first half of 2015 was $18.4 million, or $10.11 loss per share, compared to $10.2 million, or $15.75 loss per share, for the first half of 2014.
The Companys balance sheet as of June 30, 2015 showed total cash and cash equivalents of $65.8 million, including proceeds from the IPO in June.
Conference Call
Invuitys management will
discuss the Companys financial results for the second quarter and six months ended June 30, 2015, and provide a general business update during a conference call beginning at 5:00 p.m. Eastern Time today, August 11, 2015. To join the
live call, participants may dial 1-855-539-0900 (U.S.) or 1-412-455-6044 (International). To listen to the live call via Invuitys website, go to www.invuity.com, in the Events & Presentations section. A webcast replay of the call will
be available following the conclusion of the call for a period of 90 days in the Events & Presentations section of the website.
About Invuity®
Invuity, Inc. is a medical technology company focused on developing and marketing advanced
photonics devices to improve the ability of surgeons to illuminate and visualize the surgical cavity during open minimally invasive and minimal access surgery. The Companys patented Intelligent Photonics technology enables enhanced surgical precision, efficiency and safety by providing superior visualization. Clinical applications include breast and thyroid oncology, plastic reconstructive,
spine, orthopedic, cardiothoracic and general surgery among others. Invuity is headquartered in San Francisco, CA. For more information, visit www.invuity.com.
Forward-Looking Statements
This announcement contains
forward-looking statements that involve risks and uncertainties, including statements regarding market opportunities and potential results from future new initiatives. Actual results could differ materially from those projected in the
forward-looking statements as a result of certain risk factors, including, but not limited to: fluctuations in demand or failure to gain market acceptance for the Companys devices; the Companys ability to demonstrate to and gain approval
from hospitals to use the Companys devices; the highly competitive business environment for surgical medical devices; the Companys ability to sell its devices at prices that support its current business strategies; difficulty forecasting
future financial performance; protection of the Companys intellectual property; and compliance with necessary regulatory clearances or approvals. The Company undertakes no obligation to update the forward-looking information in this release.
More information about potential factors that could affect the Companys business and financial results is included in its filings with the Securities and Exchange Commission, including, without limitation, under the captions:
Managements Discussion and Analysis of Financial Condition and Results of Operations, and Risk Factors, which are on file with the Securities and Exchange Commission.
- TABLES FOLLOW -
CONTACTS:
Media:
Miranda Duncan
Waggener Edstrom
415-342-9430
media@invuity.com
Investors:
Matt Clawson
Pure Communications
949-370-8500
irdept@invuity.com
INVUITY, INC.
Condensed Statements of Operations
(In thousands, except share and per share amounts)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2015 |
|
|
2014 |
|
|
2015 |
|
|
2014 |
|
Revenue |
|
$ |
4,747 |
|
|
$ |
2,816 |
|
|
$ |
9,189 |
|
|
$ |
4,970 |
|
Cost of goods sold |
|
|
1,936 |
|
|
|
1,280 |
|
|
|
3,668 |
|
|
|
2,027 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
2,811 |
|
|
|
1,536 |
|
|
|
5,521 |
|
|
|
2,943 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative |
|
|
9,820 |
|
|
|
5,339 |
|
|
|
18,743 |
|
|
|
9,913 |
|
Research and development |
|
|
1,857 |
|
|
|
1,310 |
|
|
|
3,757 |
|
|
|
2,513 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
11,677 |
|
|
|
6,649 |
|
|
|
22,500 |
|
|
|
12,426 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(8,866 |
) |
|
|
(5,113 |
) |
|
|
(16,979 |
) |
|
|
(9,483 |
) |
Interest expense |
|
|
(504 |
) |
|
|
(352 |
) |
|
|
(873 |
) |
|
|
(722 |
) |
Interest and other income (expense), net |
|
|
24 |
|
|
|
9 |
|
|
|
(526 |
) |
|
|
37 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(9,346 |
) |
|
$ |
(5,456 |
) |
|
$ |
(18,378 |
) |
|
$ |
(10,168 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share, basic and diluted |
|
$ |
(3.20 |
) |
|
$ |
(8.40 |
) |
|
$ |
(10.11 |
) |
|
$ |
(15.75 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average shares used to compute net loss per common share, basic and diluted |
|
|
2,919,823 |
|
|
|
649,511 |
|
|
|
1,817,673 |
|
|
|
645,681 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance Sheet
as of June 30, 2015 (unaudited)
(In thousands, except share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
June 30, 2015 |
|
|
December 31, 2014 |
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
65,755 |
|
|
$ |
6,048 |
|
Accounts receivable, net |
|
|
3,237 |
|
|
|
2,798 |
|
Inventory |
|
|
4,826 |
|
|
|
4,271 |
|
Prepaid expenses and other current assets |
|
|
1,115 |
|
|
|
2,486 |
|
|
|
|
|
|
|
|
|
|
Total current assets |
|
|
74,933 |
|
|
|
15,603 |
|
Restricted cash |
|
|
1,125 |
|
|
|
1,125 |
|
Property and equipment, net |
|
|
9,037 |
|
|
|
8,541 |
|
Other non-current assets |
|
|
|
|
|
|
55 |
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
85,095 |
|
|
$ |
25,324 |
|
|
|
|
|
|
|
|
|
|
Liabilities, Convertible Preferred Stock and Stockholders Equity (Deficit) |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2,022 |
|
|
$ |
1,075 |
|
Accrued and other current liabilities |
|
|
5,094 |
|
|
|
4,162 |
|
|
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
7,116 |
|
|
|
5,237 |
|
Deferred rent |
|
|
2,831 |
|
|
|
2,676 |
|
Convertible preferred stock warrant liability |
|
|
|
|
|
|
136 |
|
Long-term debtrelated party |
|
|
14,418 |
|
|
|
9,347 |
|
|
|
|
|
|
|
|
|
|
Total liabilities |
|
|
24,365 |
|
|
|
17,396 |
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
Convertible preferred stock, $0.001 par value0 and 6,207,320 shares authorized at June 30, 2015 and December 31, 2014,
respectively; 0 and 6,056,403 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively |
|
|
|
|
|
|
73,755 |
|
Stockholders equity (deficit): |
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value10,000,000 and no shares authorized at June 30, 2015 and December 31, 2014,
respectively; no shares issued and outstanding at June 30, 2015 and December 31, 2014 |
|
|
|
|
|
|
|
|
Common stock, $0.001 par value100,000,000 and 9,189,189 shares authorized at June 30, 2015 and December 31, 2014,
respectively; 13,305,015 and 711,249 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively |
|
|
13 |
|
|
|
1 |
|
Additional paid-in capital |
|
|
147,132 |
|
|
|
2,209 |
|
Accumulated deficit |
|
|
(86,415 |
) |
|
|
(68,037 |
) |
|
|
|
|
|
|
|
|
|
Total stockholders equity (deficit) |
|
|
60,730 |
|
|
|
(65,827 |
) |
|
|
|
|
|
|
|
|
|
Total liabilities, convertible preferred stock and stockholders equity (deficit) |
|
$ |
85,095 |
|
|
$ |
25,324 |
|
|
|
|
|
|
|
|
|
|
###
INVUITY, INC. (NASDAQ:IVTY)
Historical Stock Chart
From Jun 2024 to Jul 2024
INVUITY, INC. (NASDAQ:IVTY)
Historical Stock Chart
From Jul 2023 to Jul 2024